{
    "nctId": "NCT00972023",
    "briefTitle": "DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer",
    "officialTitle": "A Pilot Study of Androgen Receptor as a Target for the Treatment of ER-/PR-/AR + Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1,
    "primaryOutcomeMeasure": "Tumor Proliferation (Percentage of Ki-67 Positive Cells)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed invasive adenocarcinoma of the breast\n\n  * Stage I (T1c), II, or III disease (AJCC staging system)\n\n    * Lesion \u2265 1 cm on breast imaging studies (mammogram, ultrasound, or MRI)\n* HER2/neu-negative tumor\n* Planning to receive dehydroepiandrosterone (DHEA) prior to surgery\n* Disease amenable to surgery with curative intent\n\n  * Scheduled to undergo surgery immediately after completion of DHEA\n* No locally advanced or metastatic disease not amenable to surgery\n* Hormone receptor status:\n\n  * Estrogen receptor- and progesterone receptor-negative tumor\n  * Androgen receptor-positive tumor\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%\n* ANC \u2265 1,000/mm\\^3\n* Platelet count \u2265 75,000/mm\\^3\n* AST and ALT \u2264 2.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Bilirubin \u2264 2 times ULN\n* Hemoglobin \\> 9 g/dL\n* Creatinine normal OR creatinine clearance \u2265 60 mL/min\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for \u2265 1 week after completion of study therapy\n* No history of allergic reactions attributed to compounds of similar chemical or biological composition to DHEA or anastrozole\n* No concurrent uncontrolled illness, including but not limited to, any of the following:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Psychiatric illness or social situation that would limit compliance with study requirements\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 5 years since prior surgery, radiotherapy, biological therapy, hormone therapy, and/or chemotherapy for invasive breast cancer\n* No other concurrent antineoplastic or antitumor agents\n* No other concurrent investigational agents",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}